Holen Sie sich die Stockscreener-App
7.48
2.19%
0.16
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - MSN
What institutional flow reveals about Arvinas Inc.2025 Key Lessons & Fast Exit and Entry Trade Guides - Newser
Published on: 2025-08-20 04:59:17 - Newser
Will Arvinas Inc. stock go up soon2025 Trading Volume Trends & Fast Moving Trade Plans - Newser
What Fibonacci levels say about Arvinas Inc. reboundPortfolio Value Summary & Low Drawdown Investment Ideas - Newser
Technical analysis overview for Arvinas Inc. stockWeekly Trade Analysis & Weekly Chart Analysis and Trade Guides - Newser
Multi asset correlation models including Arvinas Inc.2025 Analyst Calls & Verified Entry Point Detection - Newser
How high can Arvinas Inc. stock goPortfolio Value Report & Weekly Hot Stock Watchlists - Newser
Is Arvinas Inc. forming a reversal patternTrade Risk Summary & Long-Term Safe Investment Plans - Newser
Statistical indicators supporting Arvinas Inc.’s strength2025 Volatility Report & Weekly High Momentum Picks - Newser
Using Ichimoku Cloud for Arvinas Inc. technicals2025 Sector Review & Accurate Entry/Exit Alerts - Newser
What makes Arvinas Inc. stock price move sharplyMarket Movers & Technical Buy Zone Confirmation - Newser
Arvinas Inc. Nearing Breakout Level After Bounce2025 Key Lessons & Fast Gain Swing Alerts - sundaytimes.kr
Arvinas Inc. Consolidation Zone May Signal Accumulation2025 Risk Factors & Technical Pattern Recognition Alerts - kangso.co.kr
Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener
How institutional ownership impacts Arvinas Inc. stockPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
What high frequency data says about Arvinas Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - Newser
Should you wait for a breakout in Arvinas Inc.Breakout Watch & High Return Trade Guides - Newser
Strategies to average down on Arvinas Inc.July 2025 Setups & Detailed Earnings Play Strategies - Newser
Bank of America Securities Reiterates Buy Rating for Arvinas Holding Company - AInvest
Is Arvinas Inc. a speculative investmentMarket Movers & Daily Risk Controlled Trade Plans - thegnnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Arvinas Inc. stock daily chart insightsPortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Arvinas Inc.’s Price Action Aligns with Quant Signals2025 Key Highlights & Safe Capital Growth Tips - 선데이타임즈
FY2025 EPS Estimates for Arvinas Cut by Cantor Fitzgerald - MarketBeat
Can Arvinas Inc. scale operations efficientlyJuly 2025 Spike Watch & Free Safe Entry Trade Signal Reports - classian.co.kr
HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN) - MarketBeat
Leerink Partnrs Analysts Cut Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Optimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Arvinas Inc. Stock Approaches Key Moving AverageMarket Growth Summary & Weekly High Momentum Picks - newsimpact.co.kr
Will Arvinas Inc. stock benefit from AI tech trendsForecast Cut & Advanced Swing Trade Entry Plans - Newser
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment By Investing.com - Investing.com Nigeria
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts - MarketBeat
Custom watchlist performance reports with Arvinas Inc.Take Profit & Capital Efficiency Focused Ideas - Newser
Using data filters to optimize entry into Arvinas Inc.Fundamental + Technical Combined Watchlist - Newser
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Is Arvinas Inc. Stock a Good Fit for Conservative InvestorsFree Real Time Stock Movement Analysis - Newser
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Wedbush Issues Positive Forecast for Arvinas Earnings - Defense World
HC Wainwright Comments on Arvinas’ Q3 Earnings (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
1.38%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):